150 related articles for article (PubMed ID: 17195072)
1. FDG-PET in the clinical management of carcinoma of unknown primary with metastatic cervical lymphadenopathy: shifting gears from detecting the primary to planning therapeutic strategies.
Basu S; Alavi A
Eur J Nucl Med Mol Imaging; 2007 Mar; 34(3):427-8. PubMed ID: 17195072
[No Abstract] [Full Text] [Related]
2. Detection of unknown primary tumours and distant metastases in patients with cervical metastases: value of FDG-PET versus conventional modalities.
Regelink G; Brouwer J; de Bree R; Pruim J; van der Laan BF; Vaalburg W; Hoekstra OS; Comans EF; Vissink A; Leemans CR; Roodenburg JL
Eur J Nucl Med Mol Imaging; 2002 Aug; 29(8):1024-30. PubMed ID: 12173016
[TBL] [Abstract][Full Text] [Related]
3. The role of FDG PET in the management of lymphoma: what is the evidence base?
Kirby AM; Mikhaeel NG
Nucl Med Commun; 2007 May; 28(5):335-54. PubMed ID: 17414883
[TBL] [Abstract][Full Text] [Related]
4. [The role of PET-CT in detecting unknown primary tumour in patients with cervical lymph node metastases].
Fülöp M; Kásler M; Remenár E; Lengyel Z; Borbély K
Magy Onkol; 2012 May; 56(2):84-92. PubMed ID: 22629545
[TBL] [Abstract][Full Text] [Related]
5. [PET finding of primary tonsilar cancer in a man with unknown tumor].
Gil Martínez EM; Galera Ruiz H; Moya García F; González Cabezas P
Rev Esp Med Nucl; 2006; 25(4):263-4. PubMed ID: 16827990
[No Abstract] [Full Text] [Related]
6. 18F-FDG PET in non-Hodgkin's lymphoma: qualitative or quantitative?
Weber WA
J Nucl Med; 2007 Oct; 48(10):1580-2. PubMed ID: 17909256
[No Abstract] [Full Text] [Related]
7. Detection of unknown primary cancer with fluor-deoxy-glucose positron emission tomography.
Jungehülsing M; Scheidhauer K; Pietrzyk U; Eckel H; Schicha H
Ann Otol Rhinol Laryngol; 1999 Jun; 108(6):623-6. PubMed ID: 10378534
[No Abstract] [Full Text] [Related]
8. 2[F]-fluoro-2-deoxy-D-glucose positron emission tomography is a sensitive tool for the detection of occult primary cancer (carcinoma of unknown primary syndrome) with head and neck lymph node manifestation.
Jungehülsing M; Scheidhauer K; Damm M; Pietrzyk U; Eckel H; Schicha H; Stennert E
Otolaryngol Head Neck Surg; 2000 Sep; 123(3):294-301. PubMed ID: 10964310
[TBL] [Abstract][Full Text] [Related]
9. Prospective study of 18FDG-PET in the detection and management of patients with lymph node metastases to the neck from an unknown primary tumor. Results from the DAHANCA-13 study.
Johansen J; Buus S; Loft A; Keiding S; Overgaard M; Hansen HS; Grau C; Bundgaard T; Kirkegaard J; Overgaard J
Head Neck; 2008 Apr; 30(4):471-8. PubMed ID: 18023031
[TBL] [Abstract][Full Text] [Related]
10. PET evaluation of lung cancer.
Bunyaviroch T; Coleman RE
J Nucl Med; 2006 Mar; 47(3):451-69. PubMed ID: 16513615
[No Abstract] [Full Text] [Related]
11. Update on 18F-fluorodeoxyglucose/positron emission tomography and positron emission tomography/computed tomography imaging of squamous head and neck cancers.
Menda Y; Graham MM
Semin Nucl Med; 2005 Oct; 35(4):214-9. PubMed ID: 16150243
[TBL] [Abstract][Full Text] [Related]
12. 18F-FDG PET/CT in the assessment of carcinoma of unknown primary origin.
Ambrosini V; Nanni C; Rubello D; Moretti A; Battista G; Castellucci P; Farsad M; Rampin L; Fiorentini G; Franchi R; Canini R; Fanti S
Radiol Med; 2006 Dec; 111(8):1146-55. PubMed ID: 17171520
[TBL] [Abstract][Full Text] [Related]
13. Utility of combined (18)F-fluorodeoxyglucose-positron emission tomography and computed tomography in patients with cervical metastases from unknown primary tumors.
Roh JL; Kim JS; Lee JH; Cho KJ; Choi SH; Nam SY; Kim SY
Oral Oncol; 2009 Mar; 45(3):218-24. PubMed ID: 18804404
[TBL] [Abstract][Full Text] [Related]
14. The usefulness of fluorine 18-labelled deoxyglucose positron emission tomography in the investigation of patients with cervical lymphadenopathy from an unknown primary tumor.
Fogarty GB; Peters LJ; Stewart J; Scott C; Rischin D; Hicks RJ
Head Neck; 2003 Feb; 25(2):138-45. PubMed ID: 12509797
[TBL] [Abstract][Full Text] [Related]
15. Positron emission tomography and bone metastases.
Fogelman I; Cook G; Israel O; Van der Wall H
Semin Nucl Med; 2005 Apr; 35(2):135-42. PubMed ID: 15765376
[TBL] [Abstract][Full Text] [Related]
16. PET: too much of a good thing? Does the plethora of choices impact on patient management?
Divgi C; Pandit-Taskar N
Eur J Nucl Med Mol Imaging; 2005 Apr; 32(4):398. PubMed ID: 15761778
[No Abstract] [Full Text] [Related]
17. ¹⁸F-fluorodeoxyglucose positron emission tomography/computed tomography as an effective diagnostic workup in cervical metastasis of carcinoma from an unknown primary tumor.
Zhao K; Luo XM; Zhou SH; Liu JH; Yan SX; Lu ZJ; Yang SY; Lin LL; Dong MJ
Cancer Biother Radiopharm; 2012 Dec; 27(10):685-93. PubMed ID: 22834634
[TBL] [Abstract][Full Text] [Related]
18. The role of fluorodeoxyglucose positron emission tomography in cervical lymph node metastases from an unknown primary tumor.
Rusthoven KE; Koshy M; Paulino AC
Cancer; 2004 Dec; 101(11):2641-9. PubMed ID: 15517576
[TBL] [Abstract][Full Text] [Related]
19. Positron emission tomography for radiation treatment planning.
Grosu AL; Piert M; Weber WA; Jeremic B; Picchio M; Schratzenstaller U; Zimmermann FB; Schwaiger M; Molls M
Strahlenther Onkol; 2005 Aug; 181(8):483-99. PubMed ID: 16044216
[TBL] [Abstract][Full Text] [Related]
20. FDG-PET/CT for detection of the unknown primary head and neck tumor.
Johansen J; Petersen H; Godballe C; Loft A; Grau C
Q J Nucl Med Mol Imaging; 2011 Oct; 55(5):500-8. PubMed ID: 22019707
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
